Imatinib Stada Arzneimittel

Imatinib, the active ingredient in Imatinib Stada Arzneimittel, is a tyrosine kinase inhibitor presented as an oral tablet for oral use. It targets specific cancers such as chronic myeloid leukemia, gastrointestinal stromal tumor, and Philadelphia chromosome‑positive acute lymphoblastic leukemia in adult patients and is approved for use in the European Union.

GNH USA supplies Imatinib Stada Arzneimittel as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global oncology treatment needs.

Imatinib is used to treat malignancies driven by abnormal tyrosine‑kinase signaling.

- Chronic myeloid leukemia (CML): reduces leukemic cell proliferation and improves long‑term survival. - Gastrointestinal stromal tumor (GIST): inhibits tumor growth and delays disease progression. - Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): achieves remission by targeting the BCR‑ABL fusion protein.

Imatinib may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhea: loose stools that may be self‑limiting. - Edema: swelling of hands, feet or face. - Fatigue: generalized tiredness. - Muscle cramps: intermittent skeletal muscle discomfort. - Rash: mild skin eruption. - Headache: mild head pain. - Insomnia: difficulty sleeping.

Serious or Rare Side Effects: - Hepatotoxicity: elevated liver enzymes or liver injury. - Myelosuppression: neutropenia, anemia or thrombocytopenia. - Cardiotoxicity: decreased left ventricular ejection fraction. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Pulmonary arterial hypertension: rare increase in pulmonary pressure.

When prescribing Imatinib, clinicians should consider several safety measures to minimize risks. - Baseline assessment: obtain complete blood count and liver function tests before starting therapy. - Monitoring: perform regular CBC and hepatic panels during treatment. - Cardiac evaluation: assess left ventricular function in patients with pre‑existing heart disease. - Drug interactions: review concomitant medications that affect CYP3A4 metabolism. - Pregnancy and lactation: avoid use unless benefits outweigh potential fetal risks. - Store at ambient temperature: keep below 25 °C in original packaging, protect from moisture and light.

Imatinib interacts with several agents that can alter its plasma concentration or increase toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may markedly reduce Imatinib exposure. - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): can increase Imatinib levels and risk of adverse effects.

Moderate Interactions (Monitor Closely): - Acid‑reducing agents (e.g., proton pump inhibitors, antacids): may lower absorption, consider timing adjustments. - Concomitant anticoagulants (e.g., warfarin): may enhance bleeding risk; monitor INR. - Vaccines: live attenuated vaccines should be avoided during therapy.